WVE-006 for Alpha-1 Antitrypsin Deficiency

WVE-006 for Alpha-1 Antitrypsin Deficiency
80%68%57%May 8May 9May 10May 11May 12May 13May 14May 15May 16May 17May 18May 19May 20May 21May 22May 23May 24May 20 • YES 60.4%May 21 • YES 65.6%May 22 • YES 66.0%May 24 • YES 76.1%
Wave Life Sciences Ltd. ($WVE)
No stock closeNo stock closeNo stock close$7.30$6.79$6.28May 8May 9May 10May 11May 12May 13May 14May 15May 16May 17May 18May 19May 20May 21May 22May 23May 24May 8 • WVE $7.18May 11 • WVE $7.07May 12 • WVE $6.79May 13 • WVE $6.99May 14 • WVE $6.90May 15 • WVE $6.77May 18 • WVE $6.40
ResolvedPositive
Oracle Evidence
ClinicalNewsTrialPositionsReasoningOracle
YESAccepted93% confidenceGPT-5.5 (OpenAI)
Question
Will this trial show a positive result on Multiple Ascending Dose - Change from baseline in levels of serum M-AAT protein?
Found
Outcome Date
Reviewed
Summary

Sponsor clearly framed RestorAATion-2/NCT06405633 as a positive update. Multiple-dose data showed restored wild-type M-AAT: 64.4% of total AAT with 200 mg biweekly and 58.7% with 400 mg monthly, supporting a positive readout for the MAD serum M-AAT endpoint.

Sources
Sponsorir.wavelifesciences.com
Wave Life Sciences Announces Positive Update on RestorAATion-2 Trial: WVE-006 Achieves MZ-Like Phenotype Across Both Biweekly and Monthly Dosing

Positive RestorAATion-2 update: in multidose cohorts, WVE-006 restored wild-type M-AAT to 64.4% of total AAT at 200 mg biweekly and 58.7% at 400 mg monthly; total AAT reached therapeutically relevant levels.

Stats
Latest Run
Model
GPT-5.5 (OpenAI)
Runs
2 runs